Background: Facioscapulohumeral muscular dystrophy (FSHD) is
the third most common hereditary muscular dystrophy and is inherited in an
autosomal dominant manner in case of FSHD1 and as a digenic disorder in case of
the rarer FSHD2 form. FSHD is caused in both cases by the inappropriate
expression of the DUX4 gene, which in healthy individuals is silenced by the
methylation of the neighbouring D4Z4 repeats. With rare exceptions, only the
contraction of the D4Z4 repeats on the permissive 4qA haplotype on chromosome 4
causes FSHD1, while FSHD2 is caused by the demethylation of the D4Z4 repeats on
the permissive haplotype due to pathogenic variants in the genes regulating the
methylation of this region, SMCHD1, DNMT3B and LRIF1. Traditional diagnostics
of FSHD is based on Southern blot, a time- and effort-intensive method that can
be affected by single nucleotide (SNV), and copy number variants (CNV), as well
as by the similarity of the D4Z4 repeats located on chromosome 10. We aimed to
perform an independent evaluation of optical genome mapping (OGM) as an
alternative molecular diagnostic method for the detection of FSHD.
Methods: We first performed optical genome mapping with
EnFocus™ FSHD analysis using DLE-1 labeling and the Saphyr instrument, for our
patients with inconclusive diagnostic Southern blot results, negative FSHD2
results, and clinically evident FSHD. Secondly, we performed OGM in parallel
with the classical Southern blot analysis for our prospectively collected new
FSHD cases. Finally, we used panel exome sequencing of relevant genes to
confirm or exclude FSHD2.
Results: By using OGM we could resolve past cases with
diagnostically inconclusive Southern blot results as having shortened D4Z4
repeats on the permissive 4qA allele, consistent with their clinical
presentation. Results of the prospectively collected patients tested in
parallel using Southern blot and OGM showed full concordance, showing OGM to be
a useful alternative to the classical Southern blot method for detecting FSHD1.
For a patient showing clinical FSHD but no shortened D4Z4 repeat on the 4qA
allele using OGM or Southern blot, we found a likely pathogenic variant in
SMCHD1 by using exome sequencing, confirming FSHD2. We suggest OGM and panel
exome sequencing can be used consecutively to perform genetic testing in
clinical suspected FSHD.
Author(s) Details
Anja Kovanda
Clinical Institute of Genomic Medicine, University Medical
Center Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana,
Slovenia.
Borut Peterlin
Clinical Institute of Genomic Medicine, University Medical
Center Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana,
Slovenia
Please see the link:- https://doi.org/10.9734/bpi/mria/v10/8552E
